Outcomes to first-line pembrolizumab in patients with PD-L1-high (≥50%) non–small cell lung cancer and a poor performance status
Joao V. Alessi(Hospital Sírio-Libanês), Mark M. Awad(Memorial Sloan Kettering Cancer Center), Matthew D. Hellmann(AstraZeneca (United States)), Biagio Ricciuti(Harvard University), Andrew J. Plodkowski(Memorial Sloan Kettering Cancer Center), Mehmet Altan(The University of Texas MD Anderson Cancer Center), Jia Luo(Dana-Farber Cancer Institute), John V. Heymach(The University of Texas MD Anderson Cancer Center), Mizuki Nishino(Brigham and Women's Hospital), Fangxin Hong(Dana-Farber Cancer Institute), E. Jimenez-Aguilar(Hospital Universitario 12 De Octubre), Peter Sawan(Memorial Sloan Kettering Cancer Center), Hira Rizvi(Memorial Sloan Kettering Cancer Center), Zihan Wei(The People's Hospital of Guangxi Zhuang Autonomous Region), Brett W. Carter(The University of Texas MD Anderson Cancer Center)
Cited by 58
Related Papers
Gut microbiome influences efficacy of PD-1–based immunotherapy against epithelial tumors
|Science|2017|5.4k
Tumor mutational load predicts survival after immunotherapy across multiple cancer types
|Nature Genetics|2019|4.4k
OncoKB: A Precision Oncology Knowledge Base
|JCO Precision Oncology|2017|2.7k
Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
|Annals of Oncology|2018|2.3k
Neoadjuvant PD-1 Blockade in Resectable Lung Cancer
|New England Journal of Medicine|2018|2.1k